These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 27488933)

  • 21. [Comparison of antiemetic efficacy of 5-HT3 receptor antagonists in orthopedics cancer patients receiving high-dose chemotherapy].
    Takenaka M; Okamoto Y; Ikeda K; Hashimoto R; Ueda T; Kurokawa N; Takagi T; Uejima E
    Gan To Kagaku Ryoho; 2007 Mar; 34(3):403-7. PubMed ID: 17353632
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and other antiemetics.
    Hsu ES
    Am J Ther; 2010; 17(5):476-86. PubMed ID: 20844345
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative effectiveness of ramosetron for preventing chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis.
    Song HJ; Seo HJ; Son H
    Eur J Clin Pharmacol; 2016 Nov; 72(11):1289-1301. PubMed ID: 27526189
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ramosetron, a 5-HT3 receptor antagonist for the control of nausea and vomiting.
    Rabasseda X
    Drugs Today (Barc); 2002 Feb; 38(2):75-89. PubMed ID: 12532186
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does pharmacogenomics account for variability in control of acute chemotherapy-induced nausea and vomiting with 5-hydroxytryptamine type 3 receptor antagonists?
    Trammel M; Roederer M; Patel J; McLeod H
    Curr Oncol Rep; 2013 Jun; 15(3):276-85. PubMed ID: 23512709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study.
    Hilarius DL; Kloeg PH; van der Wall E; van den Heuvel JJ; Gundy CM; Aaronson NK
    Support Care Cancer; 2012 Jan; 20(1):107-17. PubMed ID: 21258948
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polymorphism in HTR3D shows different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy.
    Hammer C; Fasching PA; Loehberg CR; Rauh C; Ekici AB; Jud SM; Bani MR; Beckmann MW; Strick R; Niesler B
    Pharmacogenomics; 2010 Jul; 11(7):943-50. PubMed ID: 20602613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis.
    Slatkin NE
    J Support Oncol; 2007 May; 5(5 Suppl 3):1-9. PubMed ID: 17566383
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emerging drugs for chemotherapy-induced emesis.
    Navari RM; Province PS
    Expert Opin Emerg Drugs; 2006 Mar; 11(1):137-51. PubMed ID: 16503832
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous, oral, and the combination of intravenous and oral ramosetron for the prevention of nausea and vomiting after laparoscopic cholecystectomy: a randomized, double-blind, controlled trial.
    Ryu JH; Jeon YT; Hwang JW; Oh AY; Moon JY; Ro YJ; Kim CS; Chen C; Apfel CC; Do SH
    Clin Ther; 2011 Sep; 33(9):1162-72. PubMed ID: 21856001
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients.
    Tremblay PB; Kaiser R; Sezer O; Rosler N; Schelenz C; Possinger K; Roots I; Brockmoller J
    J Clin Oncol; 2003 Jun; 21(11):2147-55. PubMed ID: 12775740
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
    Balu S; Buchner D; Craver C; Gayle J
    Clin Ther; 2011 Apr; 33(4):443-55. PubMed ID: 21635990
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of oral versus intravenous ramosetron in prevention of acute cisplatin-induced emesis: a randomized controlled trial.
    Tantipalakorn C; Srisomboon J; Thienthong H; Pantusart A; Suprasert P; Saereesongkhun C; Eamtang S; Sutthichat A; Pautad N
    J Med Assoc Thai; 2004 Feb; 87(2):119-25. PubMed ID: 15061293
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice.
    Affronti ML; Schneider SM; Herndon JE; Schlundt S; Friedman HS
    Support Care Cancer; 2014 Jul; 22(7):1897-905. PubMed ID: 24570103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting.
    Tanaka K; Inui N; Karayama M; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Kusagaya H; Matsuura S; Uto T; Hashimoto D; Matsui T; Asada K; Suda T
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):147-153. PubMed ID: 31087137
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 5-hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis: can we safely reduce the dose of administered agents?
    Aapro M; Blower P
    Cancer; 2005 Jul; 104(1):1-18. PubMed ID: 15929119
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polymorphisms in the novel serotonin receptor subunit gene HTR3C show different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy.
    Fasching PA; Kollmannsberger B; Strissel PL; Niesler B; Engel J; Kreis H; Lux MP; Weihbrecht S; Lausen B; Bani MR; Beckmann MW; Strick R
    J Cancer Res Clin Oncol; 2008 Oct; 134(10):1079-86. PubMed ID: 18389280
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single-dose netupitant/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis.
    Navari RM; Binder G; Bonizzoni E; Clark-Snow R; Olivari S; Roeland EJ
    Future Oncol; 2021 Aug; 17(23):3027-3035. PubMed ID: 33878896
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting.
    Navari RM
    Expert Opin Drug Saf; 2016; 15(3):343-56. PubMed ID: 26699406
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians' and nurses' estimation vs. patients' reported outcomes.
    Liau CT; Chu NM; Liu HE; Deuson R; Lien J; Chen JS
    Support Care Cancer; 2005 May; 13(5):277-86. PubMed ID: 15770489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.